{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:28:03Z","timestamp":1787678883917,"version":"build-2784847793"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672209"],"award-info":[{"award-number":["81672209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871769"],"award-info":[{"award-number":["81871769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jconrel.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:21:11Z","timestamp":1594336871000},"page":"380-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Nanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?"],"prefix":"10.1016","volume":"325","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-2411","authenticated-orcid":false,"given":"Naibo","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-6585","authenticated-orcid":false,"given":"Fengjin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.07.006_bb0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0010","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0015","doi-asserted-by":"crossref","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108740","article-title":"Etanercept improved anemia and decreased hepcidin gene expression in a rat model of rheumatoid arthritis","volume":"112","author":"Elsheemy","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0025","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0035","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nn.4338","article-title":"A polarizing question: do M1 and M2 microglia exist?","volume":"19","author":"Ransohoff","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0045","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0050","doi-asserted-by":"crossref","first-page":"102369","DOI":"10.1016\/j.autrev.2019.102369","article-title":"Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases","volume":"18","author":"Di Benedetto","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.intimp.2018.10.016","article-title":"Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis","volume":"65","author":"Rana","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0060","doi-asserted-by":"crossref","first-page":"102397","DOI":"10.1016\/j.autrev.2019.102397","article-title":"Macrophage M1\/M2 polarization and rheumatoid arthritis: a systematic review","volume":"18","author":"Tardito","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0065","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3389\/fimmu.2017.01958","article-title":"M1 and M2 monocytes in rheumatoid arthritis: a contribution of imbalance of M1\/M2 monocytes to osteoclastogenesis","volume":"8","author":"Fukui","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0070","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/1346-8138.14509","article-title":"Involvement of M1\/M2 macrophages in the pathomechanisms of intralymphatic histiocytosis associated with rheumatoid arthritis","volume":"46","author":"Iwasaki","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq0305","article-title":"Mixed-effects association of single cells identifies an expanded effector CD4(+) T cell subset in rheumatoid arthritis","volume":"10","author":"Fonseka","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0085","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1136\/annrheumdis-2018-214885","article-title":"Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell","volume":"78","author":"Takeshita","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0090","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41467-018-04310-9","article-title":"Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes","volume":"9","author":"Ai","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-019-1935-6","article-title":"A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients","volume":"21","author":"Ma","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0100","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/annrheumdis-2018-214783","article-title":"TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis","volume":"78","author":"Loh","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","article-title":"Cytokines in rheumatoid arthritis - shaping the immunological landscape","volume":"12","author":"McInnes","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/BOR.0000000000000470","article-title":"What are the dominant cytokines in early rheumatoid arthritis?","volume":"30","author":"Ridgley","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12560","article-title":"Melatonin attenuates TNF-\u03b1 and IL-1\u03b2 expression in synovial fibroblasts and diminishes cartilage degradation: implications for the treatment of rheumatoid arthritis","volume":"66","author":"Huang","year":"2019","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.intimp.2019.02.029","article-title":"Taraxasterol suppresses inflammation in IL-1\u03b2-induced rheumatoid arthritis fibroblast-like synoviocytes and rheumatoid arthritis progression in mice","volume":"70","author":"Chen","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0130","doi-asserted-by":"crossref","first-page":"i472","DOI":"10.1136\/bmj.i472","article-title":"Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer","volume":"352","author":"Assassi","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00011-019-01244-w","article-title":"TNF-\u03b1\/calreticulin dual signaling induced NLRP3 inflammasome activation associated with HuR nucleocytoplasmic shuttling in rheumatoid arthritis","volume":"68","author":"Liu","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/imt-2017-0155","article-title":"Etanercept for the treatment of rheumatoid arthritis","volume":"10","author":"Zhao","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2017.11.005","article-title":"TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same?","volume":"17","author":"Rubbert-Roth","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jcsm.12189","article-title":"Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis","volume":"8","author":"Tournadre","year":"2017","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0155","doi-asserted-by":"crossref","first-page":"104402","DOI":"10.1016\/j.phrs.2019.104402","article-title":"Il-6 involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab","volume":"149","author":"Atzeni","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0160","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting Interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0165","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","article-title":"The role and therapeutic targeting of IL-6 in rheumatoid arthritis","volume":"13","author":"Narazaki","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10408398.2017.1358139","article-title":"Immune modulation by curcumin: the role of interleukin-10","volume":"59","author":"Mollazadeh","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0175","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fimmu.2018.00961","article-title":"IL-10 producing B cells ability to induce regulatory T cells is maintained in rheumatoid arthritis","volume":"9","author":"Mielle","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0180","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010920","article-title":"Inhibition of NF-\u03baB signaling pathway induces apoptosis and suppresses proliferation and angiogenesis of human fibroblast-like synovial cells in rheumatoid arthritis","volume":"97","author":"Xia","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ebiom.2018.08.035","article-title":"Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-\u03baB pathway quenches intestinal inflammation and oxidative stress injury","volume":"35","author":"Zhou","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0190","first-page":"1371","article-title":"Mangiferin suppresses CIA by suppressing the expression of TNF-\u03b1, IL-6, IL-1\u03b2, and RANKL through inhibiting the activation of NF-\u03baB and ERK1\/2","volume":"7","author":"Tsubaki","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1472-6882-14-62","article-title":"Anti-invasive effects of Celastrus Orbiculatus extract on interleukin-1 beta and tumour necrosis factor-alpha combination-stimulated fibroblast-like synoviocytes","volume":"14","author":"Li","year":"2014","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0200","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3904\/kjim.2010.25.4.429","article-title":"Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fibroblasts","volume":"25","author":"Moon","year":"2010","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030484","article-title":"Negative regulators of JAK\/STAT signaling in rheumatoid arthritis and osteoarthritis","volume":"18","author":"Malemud","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0220","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.40569","article-title":"JAK\/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis","volume":"70","author":"McGarry","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112410","article-title":"High expression of STAT3 in subcutaneous adipose tissue associates with cardiovascular risk in women with rheumatoid arthritis","volume":"18","author":"Nadali","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biotechadv.2013.09.006","article-title":"The role of ABA and MAPK signaling pathways in plant abiotic stress responses","volume":"32","author":"Danquah","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0235","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","article-title":"Signaling pathway of MAPK\/ERK in cell proliferation, differentiation, migration, senescence and apoptosis","volume":"35","author":"Sun","year":"2015","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0240","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1016\/j.molimm.2009.07.021","article-title":"Aberrant integrin activation induces p38 MAPK phosphorylation resulting in suppressed Fas-mediated apoptosis in T cells: implications for rheumatoid arthritis","volume":"46","author":"Lin","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030627","article-title":"TLR4-targeting therapeutics: structural basis and computer-aided drug discovery approaches","volume":"25","author":"Ain","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0250","doi-asserted-by":"crossref","first-page":"119974","DOI":"10.1016\/j.biomaterials.2020.119974","article-title":"The \u03b1C helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases","volume":"245","author":"Shah","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0255","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12016-019-08742-z","article-title":"Toll-like receptors, infections, and rheumatoid arthritis","volume":"58","author":"Arleevskaya","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0260","doi-asserted-by":"crossref","DOI":"10.2174\/1871530320666200427115225","article-title":"TLRs play crucial roles in regulating RA synoviocyte","author":"Luo","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0265","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0140-6736(06)69210-6","article-title":"Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial","volume":"368","author":"Vanags","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0270","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.autrev.2009.08.003","article-title":"The Wnt signaling pathway and rheumatoid arthritis","volume":"9","author":"Rabelo Fde","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0275","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrrheum.2013.25","article-title":"To Wnt or not to Wnt: the bone and joint health dilemma","volume":"9","author":"Lories","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.10.013","article-title":"Mediators of inflammation and bone remodeling in rheumatic disease","volume":"49","author":"Shaw","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0285","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1002\/jcp.27860","article-title":"Strategies toward rheumatoid arthritis therapy; the old and the new","volume":"234","author":"Abbasi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0290","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0295","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0300","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2018-213502","article-title":"Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0305","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/annrheumdis-2017-212172","volume":"77","author":"Matsuno","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0310","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0315","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0320","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","article-title":"Anakinra for the treatment of rheumatoid arthritis: a safety evaluation","volume":"17","author":"Ram\u00edrez","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0330","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0335","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012537","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents","volume":"8","author":"Eccleston","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0345","article-title":"WITHDRAWN: Celecoxib for rheumatoid arthritis","volume":"6","author":"Garner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0350","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rdc.2015.08.006","article-title":"Glucocorticoids and rheumatoid arthritis","volume":"42","author":"Ferreira","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0355","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-017-0335-7","article-title":"Glucocorticoids, inflammation and bone","volume":"102","author":"G\u00fcler-Y\u00fcksel","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0360","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.autrev.2019.05.007","article-title":"Challenges in the treatment of rheumatoid arthritis","volume":"18","author":"Conigliaro","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0365","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0375","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.berh.2019.02.003","article-title":"Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents","volume":"32","author":"Atzeni","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0380","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.semarthrit.2018.07.009","article-title":"Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to young: a systematic review and meta-analysis","volume":"48","author":"Dalal","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0385","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0390","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA interference (RNAi)-based therapeutics: delivering on the promise?","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0405","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev-phyto-080417-050044","article-title":"RNA interference mechanisms and applications in plant pathology","volume":"56","author":"Rosa","year":"2018","journal-title":"Annu. Rev. Phytopathol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrmicro.2015.14","article-title":"CRISPR-Cas adaptation: insights into the mechanism of action","volume":"14","author":"Amitai","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0415","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0420","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.20975","article-title":"Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis","volume":"52","author":"Schiffelers","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0425","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.3892\/mmr.2015.3985","article-title":"Targeted knockout of TNF-\u03b1 by injection of lentivirus-mediated siRNA into the subacromial bursa for the treatment of subacromial bursitis in rats","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0430","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2017.01.008","article-title":"Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy","volume":"122","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0435","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1096\/fj.201801513R","article-title":"Critical role of IL-1\u03b1 in IL-1\u03b2-induced inflammatory responses: cooperation with NF-\u03baBp65 in transcriptional regulation","volume":"33","author":"Singh","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0440","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/s10165-008-0131-3","article-title":"Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets","volume":"19","author":"Inoue","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0445","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00774-013-0514-1","article-title":"IL-6 negatively regulates osteoblast differentiation through the SHP2\/MEK2 and SHP2\/Akt2 pathways in vitro","volume":"32","author":"Kaneshiro","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0450","first-page":"2387","article-title":"Montelukast inhibits RANKL-induced osteoclast formation and bone loss via CysLTR1 and P2Y12","volume":"18","author":"Kang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0455","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/rheumatology\/ker327","article-title":"Hypoxia differentially affects IL-1\u03b2-stimulated MMP-1 and MMP-13 expression of fibroblast-like synoviocytes in an HIF-1\u03b1-dependent manner","volume":"51","author":"Lee","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0460","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1039\/D0NR00454E","article-title":"A novel indomethacin\/methotrexate\/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis","volume":"12","author":"Yin","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0465","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0470","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0475","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0480","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3892\/or.2017.5718","article-title":"Cancer drug delivery in the nano era: an overview and perspectives (review)","volume":"38","author":"Li","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0485","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0490","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1021\/acsbiomaterials.8b00738","article-title":"Reduction-responsive polypeptide nanogel for intracellular drug delivery in relieving collagen-induced arthritis","volume":"4","author":"Feng","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0495","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ijbiomac.2017.07.087","article-title":"Chitosan as a bioactive polymer: processing, properties and applications","volume":"105","author":"Muxika","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0500","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mt.2008.220","article-title":"Chitosan\/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model","volume":"17","author":"Howard","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0505","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2011.12.014","article-title":"Drug targeting systems for inflammatory disease: one for all, all for one","volume":"161","author":"Crielaard","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0510","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mt.2013.245","article-title":"TNF-\u03b1 gene silencing using polymerized siRNA\/thiolated glycol chitosan nanoparticles for rheumatoid arthritis","volume":"22","author":"Lee","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0515","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2015.08.025","article-title":"Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy","volume":"216","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0520","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/IJN.S146942","article-title":"In vivo therapeutic efficacy of TNF\u03b1 silencing by folate-PEG-chitosan-DEAE\/siRNA nanoparticles in arthritic mice","volume":"13","author":"Shi","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0525","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.msec.2017.12.036","article-title":"Recent advances of PLGA micro\/nanoparticles for the delivery of biomacromolecular therapeutics","volume":"92","author":"Ding","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0530","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/nnm.11.90","article-title":"Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model","volume":"6","author":"Scheinman","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0535","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jconrel.2012.05.004","article-title":"MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model","volume":"161","author":"te Boekhorst","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0540","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.nano.2019.102017","article-title":"Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy","volume":"20","author":"Sun","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0545","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nprot.2012.038","article-title":"A simple and rapid nonviral approach to efficiently transfect primary tissue\u2013derived cells using polyethylenimine","volume":"7","author":"Hsu","year":"2012","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0550","article-title":"Systemic delivery of small interfering RNA targeting the interleukin-2\/15 receptor \u03b2 chain prevents disease progression in experimental arthritis","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0555","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/nnm.13.217","article-title":"Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis","volume":"9","author":"Duan","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0560","doi-asserted-by":"crossref","first-page":"8600","DOI":"10.1016\/j.biomaterials.2012.08.008","article-title":"The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis","volume":"33","author":"Park","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0565","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2018.05.035","article-title":"Lipid nanoparticles with minimum burst release of TNF-\u03b1 siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate","volume":"283","author":"Aldayel","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0570","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12951-018-0382-x","article-title":"Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis","volume":"16","author":"Duan","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0575","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2019.06.009","article-title":"Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model","volume":"142","author":"Jansen","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0580","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA nanoparticle-mediated IL-1beta gene silencing for systemic arthritis therapy in a mouse model","volume":"27","author":"Song","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0585","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1039\/C9BM01025D","article-title":"Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy","volume":"7","author":"Zhao","year":"2019","journal-title":"Biomaterials science"},{"key":"10.1016\/j.jconrel.2020.07.006_bb0590","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11095-011-0589-0","article-title":"Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression","volume":"29","author":"Jensen","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0595","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2016.10.033","article-title":"Systemic delivery of small interfering RNA targeting nuclear factor \u03baB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles","volume":"515","author":"Kanazawa","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0600","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/03009742.2013.777779","article-title":"Silencing TNF-\u03b1 in macrophages and dendritic cells for arthritis treatment","volume":"42","author":"Ye","year":"2013","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jconrel.2020.07.006_bb0605","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1172\/JCI75673","article-title":"Peptide-siRNA nanocomplexes targeting NF-\u03baB subunit p65 suppress nascent experimental arthritis","volume":"124","author":"Zhou","year":"2014","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920303813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:55:50Z","timestamp":1759161350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920303813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":121,"alternative-id":["S0168365920303813"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}